In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Genzyme Seprafilm: Company submits premarket approval application for bioresorbable membrane designed to reduce postoperative adhesion formation in open abdominal and pelvic procedures. The PMA will undergo expedited review at FDA. Last week, Genzyme reported the results of a study showing that 51% of abdominal surgery patients treated with Seprafilm do not develop adhesions 8-12 weeks following surgery ("The Gray Sheet" Oct. 30, In Brief)...
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.